Aeterna Zentaris (AEZS) is scheduled to report its fourth-quarter financial results on March 26, Tuesday, after the regular trading hours. The specialty biopharmaceutical company is expected to post a loss of 19 cents per share, on revenue of $0.25 million, up 40% compared to the same period last year.
It may be noted the company has a remarkable history of beating street estimates.
During the same quarter last year, the company had reported a net loss of 3 cents per share on revenues of $0.9 million.
The company, which specializes in developing endocrine treatments, has seen its stock gain 156% in the trailing 52 weeks. Since the beginning of this year, the stock has increased by 37%, as investors pin their hopes on its diagnostic test Macrilen.
Macrilen is an FDA-approved prescription oral solution to test for adult growth hormone deficiency (AGHD).
The test was out-licensed to Strongbridge Ireland Limited last year for commercialization in Canada and the US. Strongbridge launched it in July last year, and AEterna will get a royalty on the sales.
READ: WHAT IS NASH AND WHICH BIOTECH FIRMS ARE VYING FOR THE FIRST-MOVER STATUS
The test got approval from European authorities earlier this year, and the management is likely to provide more updates on this during the post-earnings conference call.
AEZS has a 12-month average price target of $5.50, suggesting a 34% upside from the last close. The stock has an average rating of Moderate Buy.